等待開盤 08-20 09:00:00
-0.002
-3.12%
Grace Therapeutics submitted its New Drug Application (NDA) to the FDA for GTx-104, an injectable nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). The application includes positive results from the Phase 3 STRIVE-ON safety trial, which showed GTx-104 met its primary endpoint with a 19% reduction in clinically significant hypotension compared to oral nimodipine. The submission could trigger up to $7.6 million in warra...
06-25 12:00
Grace Therapeutics held a Type C meeting with the FDA regarding their planned NDA submission for GTx-104, which is on track for submission by mid-2025. The company reported successful completion of the STRIVE-ON trial, meeting its primary endpoint and showing potential clinical benefits compared to oral nimodipine. They secured $15 million in private placement financing, with potential for an additional $15 million, strengthening their cash posit...
06-23 12:00
证券之星消息,截至2025年6月13日收盘,恩典生命科技(02112.HK)报收于0.07港元,下跌1.39%,成交量213.8万股,成交额14.54万港元。
06-13 18:16
证券之星消息,截至2025年6月11日收盘,恩典生命科技(02112.HK)报收于0.07港元,下跌1.37%,成交量224.2万股,成交额15.63万港元。
06-11 18:09
6月2日消息,港股低开低走,恒生科技指数、国企指数跌超3%,恒生指数跌超2.5%。钢铁股早盘普跌,截至发稿,沪港联合、恩典生命科技跌超5%,重庆钢铁股份、马...
06-02 11:31
证券之星消息,截至2025年5月27日收盘,恩典生命科技(02112.HK)报收于0.12港元,与上一交易日持平,换手率0.07%,成交量106.6万股,成交额11.69万港元。
05-27 17:59